ON July 21, 2022, U.S. President Joe Biden said he had tested positive for COVID-19 and was experiencing mild symptoms. In a letter to the public, Biden’s doctor explained that the president had a slight runny nose, some fatigue and the occasional dry cough, and that Biden had already begun taking the antiviral drug Paxlovid.
Patrick Jackson, an assistant professor of infectious diseases at the University of Virginia, explains the risks that someone like Biden faces from a bout of COVID-19 and the treatments available.
The most important risk factor for developing severe COVID-19 is age. If you are 79 years old when you become infected with COVID-19, like President Biden, you are eight times more likely to become hospitalized and 140 times more likely to die compared with someone who gets COVID-19 at age 20.
Preexisting health conditions – like obesity, cancer and chronic kidney or lung disease – also increase the risk of severe illness. But Biden is reported to be fairly healthy.
Fortunately, preexisting immunity from vaccination or from a previous episode of COVID-19 is highly protective against severe disease. Researchers only have limited data on the BA.5 variant that is responsible for most recent COVID-19 cases in the U.S. – and likely Biden’s, too – but the level of protection from vaccines is likely similar to that of the previous strains BA.1 and BA.2.
While the BA.1 and BA.2 omicron variants of SARS-CoV-2 were very adept at infecting people who are vaccinated and boosted, the data shows that prior immunity from vaccines provides strong protection against severe or fatal disease.
During the first omicron wave in California, COVID-19 patients who did not have immunity from vaccination or previous infection were much more likely to be hospitalized, be admitted into an intensive care unit or die compared with people who were vaccinated and boosted.
Current best medical practice is to give antiviral treatments to patients who have recently developed mild to moderate COVID-19 symptoms and are at higher risk of severe illness. The goal of antivirals is to stop the virus from replicating in the body in order to prevent hospitalization or death.
Currently there are four antiviral drugs available in the U.S. for the treatment of COVID-19 in outpatients: nirmatrelvir-ritonavir, better known by the brand name Paxlovid, remdesivir, bebtelovimab and molnupiravir. The best drug for a particular patient depends on preexisting health conditions, accessibility and drug interactions with other medications. Paxlovid is widely used because it was shown to be highly effective in a clinical trial and is available in pill form.
Paxlovid is an oral antiviral drug that is used to treat some patients with mild to moderate COVID-19 who do not require hospitalization. Paxlovid is a combination of two medications. One is nirmatrelvir, a drug that works by disrupting the coronavirus’ ability to make functioning proteins. The other is ritonavir, an HIV drug that boosts the level of nirmatrelvir in the blood by blocking an enzyme in the liver that breaks down nirmatrelvir.
A clinical trial of Paxlovid showed that the drug significantly reduces the risk of hospitalization or death when given to infected patients within five days of their first COVID-19 symptoms. This trial looked at Paxlovid given to people who had no prior immunity to COVID-19 from vaccines or previous infection.
The effectiveness of Paxlovid in the treatment of patients who have preexisting immunity from vaccination or prior infection is less clear, though some studies suggest that older vaccinated patients may still benefit from the drug. Paxlovid has not been found to reduce symptoms or make patients feel better more quickly.
Paxlovid is not a panacea. It cannot be used for some patients who have significant kidney or liver problems, and it interacts negatively with a large number of other medications. Some patients cannot take Paxlovid because of the other drugs they use, but physicians can sometimes manage these interactions.
For example, Biden is reportedly taking a blood thinner called apixaban. This drug interacts negatively with Paxlovid. It is likely Biden’s doctor has instructed him to reduce his dose of apixaban or stop it briefly while on Paxlovid.
Biden’s doctors will be monitoring his symptoms and checking his blood oxygen level. If Biden’s symptoms – like cough, shortness of breath or fever – worsen or he needs supplemental oxygen, it is possible he would be hospitalized where he may get treated with additional drugs, including steroids.
Some patients experience an initial improvement followed by a “rebound” of their COVID-19 symptoms. It is not clear how often rebounds happen or if they are associated with COVID-19 treatment. Rebounds appear to be generally mild and not associated with hospitalization or death, though they can prolong the required period of isolation.
It is still too early to tell how mild or severe Biden’s bout of COVID-19 will be. With most mild cases only lasting around a week, the U.S. should only need to wait a few days to get a sense of what kind of fight the president is facing.
Reuters
Fri Jul 22 2022
Biden's doctor explained that the president had a slight runny nose, some fatigue and the occasional dry cough, and that Biden had already begun taking the antiviral drug Paxlovid. - Filepic
Nahas helikopter Lumut: Laporan interim siap dalam masa dua minggu - Fahmi
Menteri Pertahanan akan membuat pengumuman berhubung bantuan yang akan diberikan pada Rabu.
Gadang rayu EPU ketepikan keperluan ekuiti Bumiputera bagi pengambilan tanah Kwasa Damansara
Gadang Holdings Bhd berkata ia akan merayu kepada Unit Perancang Ekonomi (EPU) untuk mengenepikan keperluan ekuiti Bumiputera bagi memudahkan pemilikan tanah seluas 21.08 ekar di Kwasa Damansara.
Doa dan kenangan buat pejuang
Titipan doa Wartawan Ridauddin Daud buat pejuang negara yang meninggal dunia dalam nahas dua helikopter di Pangkalan TLDM. Semoga roh mereka dicucuri rahmat.
PM Vietnam cadang ASEAN jadi model transformasi digital global
Perdana Menteri Vietnam mencadangkan orientasi kejayaan untuk menjadikan ASEAN sebagai model dalam transformasi digital di peringkat global.
Proses bedah siasat selesai, penghormatan terakhir mengikut tradisi tentera laut
Ridauddin Daud membawakan perkembangan terkini penghomatan terakhir kepada 10 mangsa insiden helikopter TLDM yang terhempas di Lumut.
[TERKINI] Anak menteri besar antara enam direman bersabit kes tuntutan palsu
Anak seorang menteri besar, Pegawai kanan Pejabat MB antara enam yang direman bagi bantu siasatan pemalsuan dokumen dan tuntutan palsu berjumlah RM600,000.
Agong berkenan meriahkan Majlis Sulaman Kasih Aidilfitri Kementerian Perpaduan
Yang di-Pertuan Agong Sultan Ibrahim hari ini berkenan memeriahkan Majlis Sulaman Kasih Aidifitri Kementerian Perpaduan Negara.
[KOLUMNIS] Kawalan kendiri dapat perkukuh penguatkuasaan undang-undang AI
Tanpa kawalan kendiri, undang-undang mungkin menjadi tidak berkesan termasuklah dalam persoalan impak AI terhadap masyarakat.
Nahas helikopter Lumut: Proses bedah siasat 10 mangsa selesai - TLDM
Proses bedah siasat melibatkan 10 mangsa nahas helikopter terhempas di Lumut yang dijalankan di Jabatan Forensik Hospital Raja Permaisuri Bainun (HRPB) selesai pada jam 2.20 petang Rabu.
AWANI Ringkas: Suspek kes tembak KLIA didakwa
Ikuti rangkuman berita utama yang menjadi tumpuan sepanjang hari di Astro AWANI menerusi AWANI Ringkas.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
Biden enggan hadir pendengaran awam - Jawatankuasa Pemantauan Dewan AS
Biden menolak permintaan anggota kongres untuk memberi keterangan secara terbuka sebagai sebahagian daripada siasatan pendakwaan yang tertumpu kepada dakwaan aktiviti jenayah oleh keluarganya.
Jordan tidak benarkan perang serantau berlaku di wilayahnya - Raja Abdullah II
Raja Abdullah menekankan keperluan untuk menghentikan peningkatan konflik di rantau itu dengan segera.
Biden jangka Iran tidak akan berlengah untuk serang Israel
Biden berkata beliau tidak mahu memberi penjelasan lanjut terhadap maklumat risikan sulit diperoleh Washington mengenai rancangan Tehran.
Biden ikrar sokong Israel sekiranya diserang Iran
AS akan terus melindungi keselamatan Israel sekalipun ketika Biden dan Netanyahu sering tidak sependapat konflik di Palestin.
China berharap jadi rakan, bukan pencabar Amerika Syarikat
Perkembangan hubungan China-Amerika Syarikat (AS) yang diterajui pemimpin kedua-dua negara stabil pada masa ini, kata Perdana Menteri China Li Qiang.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
Israel "tidak melakukan secukupnya untuk melindungi pekerja bantuan" di Gaza - Biden
Presiden Amerika Syarikat Joe Biden "marah" dan "kecewa" berhubung serangan udara Israel di Gaza yang mengorbankan tujuh pekerja bantuan World Central Kitchen.
Biden menang pemilihan peringkat awal di Dakota Utara
Dalam pemilihan peringkat awal di Dakota Utara, terdapat 13 perwakilan ditawarkan dan kebanyakan pengundian dilakukan melalui undi pos.
AS hantar lebih banyak bom ke Israel
Presiden Joe Biden meluluskan perjanjian pembekalan senjata, bom dan jet tempur bernilai berbilion dolar kepada Israel secara rahsia.